Business, energy, technology, markets and global industry news from Business News Today

Nature Medicine

PharmaDeviceNews Nature Medicine
Targeted lung cancer therapy is becoming increasingly important as Johnson & Johnson expands Rybrevant across EGFR-mutated non-small cell lung cancer treatment. Representative image.
Pharma & Biotech

Ivonescimab clears half of lung tumours before surgery, but can Akeso prove lasting benefit?

Akeso's ivonescimab delivered 70.1% major pathological response in resectable lung cancer. The Phase 2 trial reveals promise and limitations.

Read More
Signatera MRD data at ASCO GU raises new questions about who really needs cystectomy
Pharma & Biotech

CatalYm’s visugromab lifted bladder cancer complete responses to 33%, but can it help patients avoid surgery?

CatalYm's visugromab lifted bladder cancer complete responses to 33% versus 8% with nivolumab alone. Can larger trials establish lasting benefit?

Read More
Representative image: Gastric cancer imaging and biomarker analysis illustrate ALX Oncology’s evorpacept results in HER2-positive, CD47-high tumors from the ASPEN-06 study.
Pharma & Biotech

Evorpacept biomarker signal deepens in HER2-positive gastric cancer as ALX Oncology shifts focus

ALX Oncology’s evorpacept raises response to 63.6% in a HER2-retained, CD47-high gastric cancer subgroup, supporting biomarker-led development.

Read More
Vero Bioscience is combining Stanford University’s proteomic organ-aging and Cell Clock technologies to develop OrganAge, a blood-based platform designed to assess biological aging across organs and cell types as the company moves toward broader consumer availability in 2027. Representative image.
Medical Devices & Diagnostics

Can one blood test reveal which cells are aging fastest? Vero brings Stanford Cell Clock into OrganAge

Vero adds Stanford Cell Clock technology to OrganAge ahead of a 2027 rollout, while clinical validation remains the key commercial test.

Read More
Tempus AI’s PRISM2 pathology foundation model showed strong retrospective performance across cancer detection, biomarker prediction and survival analysis, strengthening interest in general-purpose artificial intelligence for digital pathology. Representative image.
Medical Devices & Diagnostics

Tempus AI trained PRISM2 on 2.3m pathology slides. Can one model detect cancer and predict what happens next?

Tempus AI’s PRISM2 foundation model matched or exceeded specialised pathology products across several retrospective cancer-detection tests while also supporting biomarker and survival predictions. The results strengthen the case for general-purpose pathology artificial intelligence, but PRISM2 is not yet an FDA-authorised diagnostic device.

Read More
Neuvotion targets stroke and spinal cord injury rehabilitation with NeuStim commercial launch
Medical Devices & Diagnostics

Neuvotion NeuStim commercialization advances as brain-computer interface research gains validation

Neuvotion links its fall NeuStim launch to a Nature Medicine brain-body interface study, while the implanted system remains investigational.

Read More
A clinician-scientist reviews ocular imaging as DYP688 Phase 1 results highlight early targeted activity in metastatic uveal melanoma, even as the drug’s future development remains uncertain. Representative image.
Pharma & Biotech

A promising eye cancer drug shrank tumors in phase 1, so why did Novartis stop developing DYP688?

DYP688 showed early activity and manageable toxicity in metastatic uveal melanoma, but Novartis has halted development despite the clinical signal.

Read More
Pharma & Biotech

What Actuate Therapeutics’ Phase 2 survival data means for pancreatic oncology

Read how Actuate Therapeutics’ elraglusib survival data could reshape first-line pancreatic cancer treatment and what regulators may watch next.

Read More